Regulatory Submission

Phase 3

We help you use the review window to get launch-ready. The months your submission spends under review are either preparation time or lost time.

Phase overview

Regulatory Submission begins when you file your regulatory package with the FDA, whether a 510(k), De Novo request, or PMA, and ends when the agency issues its decision. For 510(k) submissions, this window is typically three to twelve months. For PMA submissions, it can extend significantly longer. The waiting period carries real commercial risk. Teams that use it well arrive at clearance with their commercial strategy prepared and their stakeholders engaged. Teams that don’t often face a slow and costly start to launch.

Reimbursement

Coding, coverage, and payment strategy finalized before the agency decision.

Health System Access

Strategies for hospitals, IDNs, GPOs, and value analysis committees developed ahead of clearance.

Launch Planning

Launch readiness assessment, roadmap, KPIs, and scenario plans built around the clearance timeline.

Business Model Strategy

Sales strategy and channel priorities set so the right accounts are targeted first.

Medical Affairs

Early engagement with clinical stakeholders and KOLs while the submission is under review.

NEXT PHASE

Market Clearance

With the decision granted and launch strategy in place, the program moves into activation and preparation for market entry.

Continue